NSE-listed pharmaceutical companies offering contract development and manufacturing (CDMO) services to global drug makers — from API synthesis to finished dosage forms.
Sectors represented: Healthcare
This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. locate resources. more effectively toward innovation and commercial. growth. This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. By leveraging CDMOs' streamlined procedures.
We offer a. diverse and expanding range. of pharmaceutical products,. meticulously developed to. meet the evolving clinical and. treatment needs of patients. worldwide. Our portfolio encompasses a. broad array of pharmaceutical. solutions, comprising of an. array of generic formulations developed to. meet the evolving clinical and. treatment needs of patients. worldwide.
Significant steps have been taken to improve raw material. and utilities consumption and increase manufacturing. efficiency. Building long-term relationships with key customers by. offering improved quality and service experience. Building economies of scale in manufacturing, distribution. channels and procurement to maintain cost advantage and. sustained entry barrier.
Pharmaceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years. aceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years.
It is important to interpret these. trends carefully, as chronic conditions—which account for. a significant share of treatment days—are less frequently. treated in lower-income settings due to resource constraints. Global CDMO Industry. The global pharmaceutical Contract Development and. Manufacturing Organization (CDMO) market is projected frequently.
The CDMO sector plays a pivotal role in facilitating drug. development and clinical trial activities. In CY24, the global CDMO. industry reached a market size of USD 184.90 billion, with the Asia. Pacific region making a substantial contribution to the industry's. growth. 10. clinical trial activities. In CY24, the global CDMO. industry reached a market size of USD 184.90 billion, with the Asia.
Pharmaceutical CDMO Market Size. 2023 to 2033 (USD Billion). $ 146.29. $ 156.97. $ 168.43. $ 180.72. $ 193.92. $ 208.07. $ 223.26. $ 239.56. $ 257.05. $ 275.81. $ 295.95. 20232024202520262027202820292030 l growth. Pharmaceutical CDMO Market Size. 2023 to 2033 (USD Billion). $ 146.29. $ 156.97. $ 168.43. $ 180.72. $ 193.92. $ 208.07. $ 223.26. $ 239.56. $ 257.05. $ 275.81. $ 295.95.
Manufacturing. capacity available for. third-party branded. generics. Proven capability in. delivering compliant,. export-quality batches. Contract Manufacturing (CMO) Capabilities: Bafna has strong CMO. capabilities and is ready to capitalize the experience, expertise and Proven capability in. delivering compliant,. export-quality batches.